Hims vs Ro: Comparing Two Similar Telehealth Programs

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Hims or Ro, receives no compensation from either, and includes no affiliate links.

Hims and Ro are the trickiest kind of comparison: two subscription-telehealth services that run on the same basic model. When two programs look alike, the useful question is not "which is better" but "which details actually separate them for me." This overview lays out how each is put together, what to weigh when the models overlap, and the genetic variable that outlasts whichever subscription you pick.

Inside the Hims program

Hims, part of Hims & Hers Health, follows a subscription-telehealth pattern: virtual intake, licensed-provider review, and a prescription that may be a branded FDA-approved GLP-1 or compounded semaglutide or tirzepatide from a licensed pharmacy. The current specifics appear on the Hims website.

Inside the Ro program

Ro (Roman Health) runs on the same subscription-telehealth spine, with its own intake flow, provider network, and fulfillment arrangements. Because the model rhymes with Hims, the meaningful contrasts hide in the operational details rather than the headline structure. Confirm them on the Ro website.

Evaluating two look-alike subscription services

When the frameworks match, decision-worthy differences tend to be provider type, how dose titration and follow-up are handled, shipping cadence, cancellation terms, and which specific products each currently stocks. None of these change the medicine; they change the experience and the friction around it, which is often what actually determines satisfaction.

What the trials say about the underlying drugs

The evidence base belongs to the compounds, not the storefronts. Semaglutide was studied in the STEP program (NEJM 2021) and tirzepatide in SURMOUNT (NEJM 2022), with SURMOUNT-OSA (NEJM 2024) extending tirzepatide into obstructive sleep apnea. Whether Hims or Ro delivers the molecule, the pharmacology and its trial record are the same.

A short checklist before you commit

Because the two services mirror each other, a quick checklist beats a gut call. Confirm who writes and manages your prescription, how quickly you can reach a provider for dose changes, what happens if you pause or cancel, how refills and shipping are timed, and which specific products are in stock right now. Running the same five questions against each brand own site turns two near-identical marketing pages into a decision you can actually defend, without relying on which brand name you simply happened to hear about first.

The genetic variable that outlasts any subscription

Subscriptions start and stop; your genome does not. Variants in TCF7L2, a transcription factor tied to glucose homeostasis and GLP-1 secretion, along with GLP1R and FTO, describe the metabolic baseline any protocol works against. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, mapping that baseline while never predicting your response to a specific compound.

The PlexusDx alternative

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols, sold as Semaglutide Injection ($189/month), Semaglutide Oral, Tirzepatide Injection ($289/month), and Tirzepatide Oral. The Precision Peptide Genetic Test supplies the upstream context that look-alike subscriptions leave out.

Not affiliated: PlexusDx has no commercial relationship with Hims, Ro, or any brand referenced above.

Keep reading on PlexusDx: GLP-1 Hormone, What Is GLP-1, GLP-1 What Is, GLP-1 Receptor Agonist.

Editorial note: this review is educational only. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols and is not affiliated with the brands reviewed. The Precision Peptide Genetic Test describes genetic influence on peptide pathways and does not predict medication response. Speak with a qualified provider before starting any protocol.

Frequently Asked Questions

If Hims and Ro use the same model, how do I choose?

Focus on the operational details that differ: provider type, follow-up and titration support, shipping cadence, cancellation terms, and which products each stocks now. Because the underlying model and medicine are shared, these experience factors, not the headline structure, usually decide which service suits you.

Do Hims and Ro dispense the same GLP-1 drugs?

Both can prescribe within the GLP-1 class and may offer semaglutide or tirzepatide depending on eligibility and supply. Some products are FDA-approved branded versions and others are compounded through licensed pharmacies, so verify each service current catalog before assuming the two lineups match exactly.

Is one service more legitimate than the other?

Both operate as licensed telehealth in the GLP-1 space. Legitimacy markers, such as licensed clinicians, state-licensed pharmacy partners, and clinical evaluation before prescribing, apply to each. Rather than assume, confirm current credentialing and licensure on each brand own site before committing.

Does genetic testing help when programs look identical?

Yes, because it addresses a layer neither program touches. The Precision Peptide Genetic Test maps variants like TCF7L2 that shape metabolic response, giving you context that stays relevant no matter which of two similar subscriptions you ultimately choose.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education